RTW Participates in $95 Million Financing Round in
Monte Rosa Therapeutics
RTW Venture Fund Limited (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Monte Rosa Therapeutics, Inc. ("Monte Rosa") on 12 March 2021 of its completion of a $95 million Series C financing round.
The Company, alongside other investment vehicles of RTW Investments, LP (the "Investment Manager"), confirms that it participated in the financing round together with other investment firms.
Monte Rosa is a privately held preclinical-stage biotech company discovering and developing small molecule degraders (also known as molecular glues) to eliminate disease-causing proteins. Monte Rosa plans to use the proceeds from the financing round to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities.